Polydendrons: A New Nanoparticle Platform with Nanomedicine Opportunities
Conference Recording Jun 10, 2014
About the Speaker
Professor Steve Rannard studied for his BSc (1988) and D. Phil (1991) at the University of Sussex. His D.Phil, sponsored by BP, focussed on novel block copolymers for dialysis membranes. After leaving Sussex, Steve spent 16 years in UK industry including Cookson, Courtaulds and Unilever at the Port Sunlight Laboratories. He is the cofounder and Vice Chair of the British Society for Nanomedicine and has led the foundation of two spinout companies, IOTA NanoSolutions Limited and Hydra Polymers Limited. He joined the University of Liverpool in September 2007 where he held a Royal Society Industry Fellowship and an IOTA NanoSolutions Industry Fellowship until 2010. His current research interests include the utilisation of different nanotechnologies in healthcare applications.Abstract
The formation of polymeric nanoparticles that are able to permeate gut monolayers, and deliver nanoparticles into the bloodstream, is a challenge to nanomedicine but allows the benefits of circulating nanoparticles without the need for injection. We have developed a new polymer architecture – termed hyperbranched polydendrons – that mimic dendrimers but provide considerable benefits at expected reduced costs. Through combinations of branched vinyl polymerisation, linear-dendritic hybrid concepts and controlled polymerisation, complex polymer architectures that nanoprecipitate to form uniform nanoparticles have been generated. Encapsulation is possible and preliminary data has shown a lack of cytotoxicity with, but significant permeation through, gut epithelium monolayers. Our initial data and synthesis strategy is presented with options outlined for future development.